NASDAQ:ANAB
AnaptysBio Inc Stock News
$23.94
-0.670 (-2.72%)
At Close: Jul 02, 2024
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
06:46pm, Thursday, 09'th May 2024
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.64 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $1.58 per share a year ago.
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
04:15pm, Thursday, 09'th May 2024
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial r
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive t
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the execut
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 02'nd May 2024
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
05:56am, Wednesday, 01'st May 2024
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength
Actym Therapeutics Appoints Thomas Smart as CEO
09:00am, Wednesday, 24'th Apr 2024
BERKELEY, Calif. , April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
BTIG Research Predicts Over 118% Rally for These 3 Stocks
02:19pm, Monday, 15'th Apr 2024
The stock market may have pulled back a bit from the all-time high reached late last month but the S&P 500 remains 7.4% higher in 2024. Technology stocks continue to be top performers with Super Micro
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
07:00pm, Friday, 12'th Apr 2024
A major bank initiated coverage of the biotech. It recommended a buy, speculating that the share price could double and then some.
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
03:41pm, Tuesday, 09'th Apr 2024
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock
01:01pm, Thursday, 14'th Mar 2024
AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade
10:56am, Thursday, 14'th Mar 2024
The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates
06:31pm, Monday, 11'th Mar 2024
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.59 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $0.93 per share a year ago.
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
04:15pm, Monday, 11'th Mar 2024
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating
Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting
09:15am, Thursday, 29'th Feb 2024
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani